Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS plus trifluridine–tipiracil and bevacizumab versus trifluridine–tipiracil and bevacizumab in liver-dominant metastatic colorectal cancer
NL-OMON59755Phase 2Recruiting
- Sponsor
- Delcath Systems
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of melphalan, trifluridine + tipiracil and bevacizumab in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Delcath Systems. Primary endpoint: hepatic progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
melphalantrifluridine + tipiracilbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59755.